S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
2 Long-Term EV Plays Trading Under $20
The 3-Stock Retirement Blueprint (Ad)
Are These 3 Video Game Stocks Now In Play?
Agilent Technologies Proves Its Worth VS Illumina 
Target’s Results Cap Upside Potential For Retail Stocks 
Sell every Stock except ONE (Ad)
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Egypt's central bank governor resigns as economic woes mount
Sell every Stock except ONE (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
2 Long-Term EV Plays Trading Under $20
The 3-Stock Retirement Blueprint (Ad)
Are These 3 Video Game Stocks Now In Play?
Agilent Technologies Proves Its Worth VS Illumina 
Target’s Results Cap Upside Potential For Retail Stocks 
Sell every Stock except ONE (Ad)
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Egypt's central bank governor resigns as economic woes mount
Sell every Stock except ONE (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
2 Long-Term EV Plays Trading Under $20
The 3-Stock Retirement Blueprint (Ad)
Are These 3 Video Game Stocks Now In Play?
Agilent Technologies Proves Its Worth VS Illumina 
Target’s Results Cap Upside Potential For Retail Stocks 
Sell every Stock except ONE (Ad)
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Egypt's central bank governor resigns as economic woes mount
Sell every Stock except ONE (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
2 Long-Term EV Plays Trading Under $20
The 3-Stock Retirement Blueprint (Ad)
Are These 3 Video Game Stocks Now In Play?
Agilent Technologies Proves Its Worth VS Illumina 
Target’s Results Cap Upside Potential For Retail Stocks 
Sell every Stock except ONE (Ad)
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Egypt's central bank governor resigns as economic woes mount
Sell every Stock except ONE (Ad)
NASDAQ:LBPS

4D pharma - LBPS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$1.65
$1.65
50-Day Range
$1.56
$3.40
52-Week Range
$1.50
$11.09
Volume
N/A
Average Volume
N/A
Market Capitalization
$37.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About 4D pharma

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Receive LBPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

LBPS Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
4D pharma reports FY results
ACHR,EBON and GENI among pre market gainers
See More Headlines

Receive LBPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

LBPS Company Calendar

Today
8/17/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LBPS
Fax
N/A
Employees
92
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$720,000.00
Book Value
$1.44 per share

Miscellaneous

Free Float
11,810,000
Market Cap
$37.19 million
Optionable
Not Optionable
Beta
0.97

Key Executives

  • Mr. Duncan Joseph Peyton (Age 52)
    CEO & Exec. Director
    Comp: $302.79k
  • Dr. Alexander James Stevenson Ph.D. (Age 50)
    Chief Scientific Officer & Exec. Director
    Comp: $259.88k
  • Mr. John Brendan Doyle (Age 44)
    Chief Financial Officer
  • Ms. Fay Weston
    Head of Investor Relations
  • Mr. Adrian Murray
    Gen. Counsel (Interim)
  • Mr. Glenn Dourado
    Exec. VP of Corp. Devel.
  • Ms. Lucy Christie
    VP of HR
  • Mr. Christophe Carite
    Sr. VP of CMC & Process Devel.
  • Ms. Imke Mulder
    Exec. VP of Research













LBPS Stock - Frequently Asked Questions

Should I buy or sell 4D pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 4D pharma in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" LBPS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LBPS, but not buy additional shares or sell existing shares.
View LBPS analyst ratings
or view top-rated stocks.

What is 4D pharma's stock symbol?

4D pharma trades on the NASDAQ under the ticker symbol "LBPS."

What is 4D pharma's stock price today?

One share of LBPS stock can currently be purchased for approximately $1.65.

How much money does 4D pharma make?

4D pharma (NASDAQ:LBPS) has a market capitalization of $37.19 million and generates $720,000.00 in revenue each year.

How can I contact 4D pharma?

4D pharma's mailing address is 9 BOND COURT 5TH FLOOR, LEEDS X0, LS1 2JZ. The official website for the company is www.4dpharmaplc.com. The company can be reached via phone at 44-0-11-3895-0130 or via email at ir@4dpharmaplc.com.

This page (NASDAQ:LBPS) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.